Jump to content
  • mission_statement.pngrrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Mission Statement

    The Rosacea Research & Development Institute [RRDi] is the first non-profit organization made by rosaceans for rosacea sufferers that will collect donations for rosacea research to be performed by physicians and biomedical research scientists and includes these specific goals:

    Goal # 1: To be the first non profit organization for rosacea patient advocacy and to find the cure for rosacea. 

    Goal # 2: To have a majority of rosaceans the right to vote who sits on the board of directors.

    Goal # 3: To make this the first rosacea specific non profit organization to utilize most of the donations for research and treatment development. This is in stark contrast to non profit organizations that spend 50% to 60% of their donations on paying their staff, board of directors, conventions for professional members or to pay private contractors for services.

    Goal # 4: To allow rosacea sufferers to guide where and how the money is spent on rosacea research and be the first non profit organization to allow rosaceans to be members of the corporation. Until June 7, 2004, the date of incorporation, there had been no other non profit organization that allowed input from rosacea sufferers.

    Goal # 5: To attain a level such that the RRDi can directly impact medical articles published on the subject, information disseminated to physicians and rosacea sufferers and apply positive pressure on the medical community.

    Goal #6: Continue to publish the Journal of the RRDi and fund all authors who contribute an article.

    Goal #7: To allow volunteer members to have a platform to voice their concerns about rosacea and to contribute information about rosacea. Our goal is 10K members. 

    For more information on how and why this non profit organization for rosacea was formed click here.

    Our Charter can be read by clicking here.

     

  • Member Statistics

    • Total Members
      1,375
    • Most Online
      499

    Newest Member
    Kristyna Krueger
    Joined
  • image.png.9c7b476f653b05bf0b4220389b0df3

  • Posts

    • Related Articl Coptis chinensis Franch Directly Inhibits Proteolytic Activation of Kallikrein 5 and Cathelicidin Associated with Rosacea in Epidermal Keratinocytes. Molecules. 2020 Nov 26;25(23): Authors: Roh KB, Ryu DH, Cho E, Weon JB, Park D, Kweon DH, Jung E Abstract Rosacea is a common and chronic inflammatory skin disease that is characterized by dysfunction of the immune and vascular system. The excessive production and activation of kallikerin 5 (KLK5) and cathelicidin have been implicated in the pathogenesis of rosacea. Coptis chinensis Franch (CC) has been used as a medicinal herb in traditional oriental medicine. However, little is known about the efficacy and mechanism of action of CC in rosacea. In this study, we evaluate the effect of CC and its molecular mechanism on rosacea in human epidermal keratinocytes. CC has the capacity to downregulate the expression of KLK5 and cathelicidin, and also inhibits KLK5 protease activity, which leads to reduced processing of inactive cathelicidin into active LL-37. It was determined that CC ameliorates the expression of pro-inflammatory cytokines through the inhibition of LL-37 processing. In addition, it was confirmed that chitin, an exoskeleton of Demodex mites, mediates an immune response through TLR2 activation, and CC inhibits TLR2 expression and downstream signal transduction. Furthermore, CC was shown to inhibit the proliferation of human microvascular endothelial cells induced by LL-37, the cause of erythematous rosacea. These results demonstrate that CC improved rosacea by regulating the immune response and angiogenesis, and revealed its mechanism of action, indicating that CC may be a useful therapeutic agent for rosacea. PMID: 33256158 [PubMed - in process]  {url} = URL to article Full Text: molecules-25-05556.pdf Et Cetera Cathelicidin Peptide LL-37 and Vitamin D3
×
×
  • Create New...